Antitumor potential of fibulin-5 in breast cancer cells depends on its RGD cell adhesion motif
dc.creator | Mohamedi Y. | |
dc.creator | Fontanil T. | |
dc.creator | Cobo T. | |
dc.creator | Vega J.A. | |
dc.creator | Cobo J.L. | |
dc.creator | Pérez-Basterrechea M. | |
dc.creator | Cobo J. | |
dc.creator | Obaya Á.J. | |
dc.creator | Cal S. | |
dc.date.accessioned | 2020-09-02T22:23:04Z | |
dc.date.accessioned | 2022-11-08T20:27:59Z | |
dc.date.available | 2020-09-02T22:23:04Z | |
dc.date.available | 2022-11-08T20:27:59Z | |
dc.date.created | 2020-09-02T22:23:04Z | |
dc.date.issued | 2019 | |
dc.identifier | 53, 1, 87-100 | |
dc.identifier | 10158987 | |
dc.identifier | https://hdl.handle.net/20.500.12728/5355 | |
dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/5146648 | |
dc.language | en | |
dc.publisher | Cell Physiol Biochem Press GmbH & Co KG | |
dc.subject | Breast cancer | |
dc.subject | Fibulin | |
dc.subject | RGD motif | |
dc.subject | Tumor microenvironment | |
dc.subject | arginylglycylaspartic acid | |
dc.subject | arginylglycylglutamine | |
dc.subject | complementary DNA | |
dc.subject | fibulin 5 | |
dc.subject | scleroprotein | |
dc.subject | tripeptide | |
dc.subject | unclassified drug | |
dc.subject | very late activation antigen 5 | |
dc.subject | vitronectin receptor | |
dc.subject | arginyl-glycyl-aspartic acid | |
dc.subject | cadherin | |
dc.subject | FBLN5 protein, human | |
dc.subject | oligopeptide | |
dc.subject | recombinant protein | |
dc.subject | scleroprotein | |
dc.subject | vimentin | |
dc.subject | animal experiment | |
dc.subject | animal model | |
dc.subject | antineoplastic activity | |
dc.subject | Article | |
dc.subject | breast cancer | |
dc.subject | breast cancer cell line | |
dc.subject | carcinogenesis | |
dc.subject | cell adhesion | |
dc.subject | cell culture | |
dc.subject | cell proliferation | |
dc.subject | cell viability assay | |
dc.subject | controlled study | |
dc.subject | DNA sequence | |
dc.subject | extracellular matrix | |
dc.subject | Fbln5 gene | |
dc.subject | gene | |
dc.subject | human | |
dc.subject | human cell | |
dc.subject | male | |
dc.subject | mouse | |
dc.subject | MTT assay | |
dc.subject | nonhuman | |
dc.subject | priority journal | |
dc.subject | protein expression | |
dc.subject | protein function | |
dc.subject | protein motif | |
dc.subject | protein protein interaction | |
dc.subject | site directed mutagenesis | |
dc.subject | allotransplantation | |
dc.subject | animal | |
dc.subject | Bagg albino mouse | |
dc.subject | biosynthesis | |
dc.subject | breast tumor | |
dc.subject | cell motion | |
dc.subject | drug effect | |
dc.subject | female | |
dc.subject | genetics | |
dc.subject | metabolism | |
dc.subject | neoplasm | |
dc.subject | pathology | |
dc.subject | tumor cell line | |
dc.subject | Animals | |
dc.subject | Breast Neoplasms | |
dc.subject | Cadherins | |
dc.subject | Cell Adhesion | |
dc.subject | Cell Line, Tumor | |
dc.subject | Cell Movement | |
dc.subject | Cell Proliferation | |
dc.subject | Extracellular Matrix Proteins | |
dc.subject | Female | |
dc.subject | Humans | |
dc.subject | Male | |
dc.subject | Mice | |
dc.subject | Mice, Inbred BALB C | |
dc.subject | Mutagenesis, Site-Directed | |
dc.subject | Neoplasms | |
dc.subject | Oligopeptides | |
dc.subject | Recombinant Proteins | |
dc.subject | Transplantation, Homologous | |
dc.subject | Vimentin | |
dc.title | Antitumor potential of fibulin-5 in breast cancer cells depends on its RGD cell adhesion motif | |
dc.type | Article |